Zealand Pharma (Denmark) Performance
| ZEAL Stock | DKK 598.00 0.50 0.08% |
On a scale of 0 to 100, Zealand Pharma holds a performance score of 8. The firm maintains a market beta of 0.33, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Zealand Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Zealand Pharma is expected to be smaller as well. Please check Zealand Pharma's standard deviation, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to make a quick decision on whether Zealand Pharma's historical returns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Zealand Pharma AS are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Zealand Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 960.2 M | |
| Total Cashflows From Investing Activities | -18.1 M |
Zealand |
Zealand Pharma Relative Risk vs. Return Landscape
If you would invest 45,440 in Zealand Pharma AS on January 20, 2024 and sell it today you would earn a total of 14,360 from holding Zealand Pharma AS or generate 31.6% return on investment over 90 days. Zealand Pharma AS is generating 0.5628% of daily returns and assumes 5.2912% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than Zealand, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Zealand Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zealand Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zealand Pharma AS, and traders can use it to determine the average amount a Zealand Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1064
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ZEAL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.29 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.56 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Zealand Pharma is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zealand Pharma by adding it to a well-diversified portfolio.
Zealand Pharma Fundamentals Growth
Zealand Stock prices reflect investors' perceptions of the future prospects and financial health of Zealand Pharma, and Zealand Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zealand Stock performance.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 10.33 B | |||
| Shares Outstanding | 51.28 M | |||
| Price To Earning | 12.66 X | |||
| Price To Book | 27.77 X | |||
| Price To Sales | 36.73 X | |||
| Revenue | 292.57 M | |||
| EBITDA | (982.6 M) | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 29.66 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (23.13) X | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | 154 M | |||
| Current Asset | 517 M | |||
| Current Liabilities | 54 M | |||
About Zealand Pharma Performance
To evaluate Zealand Pharma AS Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Zealand Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Zealand Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Zealand Pharma AS market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Zealand's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.Things to note about Zealand Pharma AS performance evaluation
Checking the ongoing alerts about Zealand Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zealand Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zealand Pharma AS is way too risky over 90 days horizon | |
| Zealand Pharma AS appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M. | |
| Zealand Pharma AS has accumulated about 1.28 B in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 29.66. | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Zealand Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zealand Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Zealand Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zealand Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zealand Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zealand Pharma's stock. These opinions can provide insight into Zealand Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zealand Pharma AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Zealand Stock analysis
When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |